Shifa Taj

Shifa Taj

Auto-generated profile, based on publicly available information

Shifa Taj

Clinical and Administrative Pharmacy, College of Pharmacy University of Georgia Athens Georgia USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2025 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
STShifa Taj
Shifa Taj
MZMohammed Zuber
Mohammed Zuber
MRMuhammad Rashid
Muhammad Rashid
MCManik Chhabra
Manik Chhabra
KUKrishna Undela
Krishna Undela
LZLORENZO VILLA ZAPATA
LORENZO VILLA ZAPATA
Aims: Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely used for type 2 diabetes mellitus and obesity, with once‐weekly dosing that supports adherence. However, injection‐site reactions (ISRs) and dermatologic events have been recognised, ranging from mild local events to rare systemic hypersensitivity reactions that may cause discontinuation. To evaluate dermatologic and ISR safety of GLP‐1 RAs through a meta‐analysis of randomised controlled trials (RCTs) and disproportionality analysis of data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS). Materials and Methods: PubMed, Embase and Web of Science were searched through December 2024 to identify RCTs reporting ISR or dermatologic outcomes for GLP‐1 RAs. Random‐effects meta‐analysis synthesised trial evidence. A retrospective disproportionality analysis of FAERS data evaluated all approved GLP‐1 RAs. Lower bound reporting odds ratios (LB ROR), proportional reporting ratios (PRR) and information components (IC) were calculated. Results: The pooled meta‐analysis of 14 RCTs that reported ISRs (4861 patients; 396 ISR events) showed increased ISR risk with GLP‐1 RAs versus comparators (risk ratio 3.55; 95% confidence interval, 2.35–5.36; I 2 = 41.4%). Dermatologic events were infrequent and not significantly elevated. FAERS data analysis revealed potential ISR signals for exenatide and dulaglutide. Exenatide was associated with injection‐site haemorrhage (PRR: 27.6; LB ROR: 29.4; IC 025 : 4.6). Dulaglutide showed disproportionate reporting for injection‐site haemorrhage (PRR: 11.5; LB ROR: 11.5; IC 025 : 3.4). Conclusions: GLP‐1 RAs are consistently linked to higher ISR risk, especially with exenatide and dulaglutide, while generalised dermatologic events are rare. Clinicians should counsel patients about ISR risk to support adherence and optimise outcomes.

23 June 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
MZMohammed Zuber
Mohammed Zuber
SEShaimaa Elshafie
Shaimaa Elshafie
STShifa Taj
Shifa Taj
LZLORENZO VILLA ZAPATA
LORENZO VILLA ZAPATA
CAR T-cell therapy has transformed the treatment of B-cell non-Hodgkin Lymphoma (NHL), yet treatment failure remains a major concern. Clinical trial data indicate relapse rates up to 50% within six months, but real-world evidence on salvage therapy patterns and financial burdens is limited. This study aims to assess the risk of CAR T failure risk, characterize subsequent therapeutic strategies, and quantify patient out-of-pocket (OOP) health care costs. We conducted a retrospective cohort study using the Merative MarketScan database (2017-2022), identifying adult patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), or primary mediastinal large B-cell lymphoma (PMBCL) who received CAR-T therapy. Additional therapy post-index indicated relapse, with cumulative risk estimated via Kaplan-Meier analysis. OOP costs, including copayments, coinsurance, and deductibles, were calculated. Among 224 eligible patients (median age: 57 years, 70% male, 83% DLBCL), 85 (38%) initiated subsequent therapy, with a cumulative failure risk of 36% at six months and 48% at 12 months. Lenalidomide was the most common salvage therapy in DLBCL. Six-month total OOP costs distributed across 121 patients were $273,676, with outpatient claims comprising 67%. Patients requiring additional therapy had higher mean OOP costs ($3,221 vs. $1,806), with some reaching $38,889. This study underscores the persistent need for effective salvage therapy options and the financial burden of treatment failure. As CAR T-cell therapy is increasingly utilized in earlier treatment lines, future research should focus on optimizing post-CAR T-cell management and mitigating financial toxicity.

1 August 2024 in Current Reviews in Clinical and Experimental Pharmacology
Verified
Journal Article
Closed access
PDF file
STShifa Taj
Shifa Taj
MZMohammed Zuber
Mohammed Zuber
VHVidhyashree Ballagere Hanumanthaiah
Vidhyashree Ballagere Hanumanthaiah
RVRajesh Venkataraman
Rajesh Venkataraman
SPSathish Kumar Puttegowda
Sathish Kumar Puttegowda
SKSai Kiran
Sai Kiran
Background: A substantial number of research studies on metronidazole-related cutaneous symptoms have recently been published. Our objective was to identify and evaluate descriptive studies that described metronidazole-related skin manifestations, therapeutic interventions, and consequences. Methodology: A comprehensive literature search was carried out in the PubMed, Scopus, and grey literature databases from inception to April 2022 without any constraints, as well as a snowball search in Google and a search in Google Scholar. Descriptive articles describing metronidazole-related cutaneous manifestations were considered for the review. Two distinct reviewers carried out the research selection, data extraction, and quality assessment; any discrepancies were resolved by consensus with the third reviewer. Results: About 24 out of 4648 descriptive studies, including 26 patients (20 Female patients and 6 male patients), were included in this review. The included studies comprised a range of ages from 16 to 78 years old. Metronidazole was indicated for the treatment of bacterial vaginosis, trichomoniasis, sepsis, anti-infection therapy, perforated appendicitis, rosacea, vaginal discharge, dysentery, acne rosacea, trichomonal vaginitis, lichen planus, liver abscess, facial rosacea, intestinal amoebiasis, and gingivitis. Fixed drug eruption was the most common skin manifestation which was reported in 7 cases included in this review. Cutaneous manifestations were ameliorated by cessation of the offending drug and by apportioning antihistamines, topical steroids, parenteral corticosteroids, emollients, and topical moisturizers. Conclusion: Clinicians and healthcare professionals should be cognizant of the potential cutaneous adverse drug reactions (CADRs) induced by metronidazole to mitigate fatal circumstances. The management of the CADRs appears to respond effectively with immediate drug discontinuation and supportive therapy.